IP Library Granted Patent US 9,631,182
Granted Patent B2
US 9,631,182 · App. 13/615,041 · Granted Apr 25, 2017

Patent

Inventors: Elena Bolchakova (Union City, CA); James Rozzelle (San Francisco, CA)
Assignee: Applied Biosystems, LLC
C12N9/1241C12N9/1252C12P19/34Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,631,182
App. No.
13/615,041
Granted
Apr 25, 2017
Kind
B2
Abstract

The invention provides nucleic acids and polypeptides for nucleic acid polymerases from a thermophilic organism, Thermus brockianus . The invention also provides methods for using these nucleic acids and polypeptides.

Claims (14)

1. A mutant polymerase having at least 98% amino acid sequence identity to SEQ ID NO:9; wherein said polymerase comprises a G→D and/or a F→Y mutation corresponding to position 43 and/or position 665 of SEQ ID NO:9, respectively.

2. A mutant polymerase having at least 98% amino acid sequence identity to SEQ ID NO:9; wherein said polymerase comprises a G→D and/or a F→Y mutation corresponding to position 43 and/or position 665 of SEQ ID NO:9, respectively, made by a method comprising incubating a host cell under conditions sufficient for RNA transcription and translation comprising a nucleic acid encoding said mutant nucleic acid polymerase operably linked to a promoter.

3. The mutant polymerase of claim 2 , wherein said nucleic acid comprises a nucleic acid sequence with at least 98% nucleic acid sequence identity to SEQ ID NO:1.

4. The mutant polymerase of claim 1 , wherein said polymerase has DNA polymerase activity between 50,000 U/mg and 500,000 U/mg.

5. The mutant polymerase of claim 1 , wherein said polymerase lacks 5′ to 3′ exonuclease activity.

6. The mutant polymerase of claim 1 , wherein said polymerase lacks discrimination against dideoxynucleotide triphosphates (ddNTPs).

7. The mutant polymerase of claim 1 , wherein said polymerase is thermostable.

8. The mutant polymerase of claim 1 , wherein said polymerase comprises reverse transcriptase activity.

9. The mutant polymerase of claim 1 , wherein said mutant polymerase has reduced bias against dideoxynucleotide triphosphates (ddNTP) incorporation compared to a corresponding wild type polymerase.

10. The mutant polymerase of claim 1 , wherein said mutant polymerase has reduced 5′ to 3′ exonuclease activity compared to a corresponding wild type polymerase.

11. The mutant polymerase of claim 1 , wherein said mutant polymerase has reduced 5′ to 3′ exonuclease activity and reduced bias against dideoxynucleotide triphosphates (ddNTP) incorporation compared to a corresponding wild type polymerase.

12. The mutant polymerase of claim 1 , wherein said mutant polymerase lacks 5′ to 3′ exonuclease activity and lacks discrimination against dideoxynucleotide triphosphates (ddNTPs).

13. The mutant polymerase of claim 1 , wherein said mutant polymerase is a mutant Thermus brockianus polymerase.

14. The mutant polymerase of claim 1 , wherein said mutant polymerase comprises SEQ NO:11, 13, or 15.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2016
From: ROZZELLE, JAMES; BOLCHAKOVA, ELENA
To: APPLERA CORPORATION
Reel/Frame 039640/0633 →
MERGER Recorded Sep 6, 2016
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 039640/0722 →
MERGER Recorded Sep 6, 2016
From: ATOM ACQUISITION CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 039640/0806 →
MERGER Recorded Sep 6, 2016
From: ATOM ACQUISITION, LLC & APPLIED BIOSYSTEMS, INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 039640/0900 →
Continuity (4)
Continuation 11300194 · Dec 13, 2005
Division 10302817 · Nov 22, 2002
Provisional Application 60334434 · Nov 30, 2001
Related Publication 20130089865A1 · Apr 11, 2013